Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 80 25 versus SECTRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE 80 25 versus SECTRAL.
INDERIDE-80/25 vs SECTRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Selective beta-1 adrenergic receptor antagonist; negative chronotropic and inotropic effects, reduces cardiac output, decreases renin release.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
Adult: 200–400 mg orally once daily, initially; may increase to 400–800 mg daily in divided doses (e.g., 200 mg twice daily). Maximum 800 mg/day. Route: Oral.
None Documented
None Documented
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life: 8-13 hours; clinically, this supports once-daily dosing, but steady-state is achieved within 2-3 days.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Renal: ~30-40% unchanged; biliary/fecal: ~20-30% as metabolites and parent compound; total renal clearance accounts for 50-70% of elimination.
Category C
Category C
Beta Blocker and Thiazide Diuretic
Beta Blocker